Pharmaceutical Clinical Trials

Home Products
Solutions Supplies
Services News & Events
Contact us

The Challenge

Projecting painful adverse effects in clinical settings is a formidable challenge in pharmacological trials. Gaining objective insight to such a subjective parameter is difficult to achieve in the laboratory.

Why QST?

Thermal testing is essential in the scientific evaluation of small-caliber A-Delta & C-Fibers, the primary transmitters of thermal and pain sensation. Quantitative Sensory Testing (QST), widely regarded as the “Gold Standard” of thermal testing, is the only test that quantitatively assesses function of somatic small fibers – from peripheral receptors through their central nervous system connections

Applying Medoc Solutions in Pharmaceutical Trials

With clear benefits to the pharmaceutical industry, the PATHWAY system helps streamline clinical trial scenarios by:

Driving decision making between multiple compounds
Reducing statistical sample size
Providing potential efficacy data coming out of various Phases of Pharmaceutical trials
Potentially reducing time to market
Defining best dosages

Medoc’s TSA-II, VSA and PATHWAY systems can demonstrate small-fiber function not revealed through Nerve Conduction Velocity. These solutions can document indications of neural activity and quantitative evidence of CNS activity and response. Armed with this documentation, researchers can complete trials faster, and achieve more reliable results that will reduce time-to-market for valuable treatments and drugs.

Specifically for clinical trials, QST has proven to be a sensitive detection tool for sub-clinical neuropathy, and helpful in evaluating toxic effects on nerve function. Medoc systems are currently being used by Pfizer, GSK, Merck, Astra Zeneca, Quintiles, Skye Pharma, Sigma Tau, Viatris and others in initial and advanced clinical trials.